Now showing items 11-17 of 17
In Vitro release of hypothalamic [beta]-endorphin [beta]E by arginine vasopressin, corticotropin-releasing hormone and 5-hydroxytryptamine: Evidence for release of opioid active and inactive [beta]E forms
(Elsevier, 1990-05)
The aims of the present experiments were: 1) to test whether substances which modulate beta-endorphin-immunoreactive [beta]E-ir release from the pituitary gland might act similarly in hypothalamic tissue; and 2) to further ...
Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo
(Elsevier, 1994-03)
Side effects play a significant role in the selection of drugs to be used in panic disorder/agoraphobia whose polyphobic symptomatology often includes a suspiciousness about taking drugs and a fear of undesired side effects ...
TRH attenuates scopolamine-induced memory impairment in humans
(Springer-Verlag, 1990-03)
The brain tripeptide thyrotropin-releasing hormone (TRH) has been demonstrated to facilitate cholinergic neurotransmission. To test its interaction with the cholinergic system in humans, high-dose TRH (0.5 mg/kg) or placebo ...
Characterization of pro-opiomelanocortin processing in heterologous neuronal cells that express PC2 mRNA
(Elsevier, 1993-05)
We have investigated processing of monkey pro-opiomelanocortin (POMC) following transfection into heterologous neuronal Neuro 2A (N2A) cells. In several separately transfected stable cell lines (termed N2A/POMC2-like; N = ...
Controlled dosing of nicotine via an I ntranasal N icotine A erosol D elivery D evice (INADD)
(Springer-Verlag, 1992-09)
The present report describes an I ntranasal N icotine A erosol D elivery D evice (INADD) employing an artist's airbrush as aerosolizer and precise, electromechanical control of spray duration. It was designed for the ...